Abbvie has a total of 47143 patents globally, out of which 17684 have been granted. Of these 47143 patents, more than 57% patents are active. The United States of America is where Abbvie has filed the maximum number of patents, followed by Europe and Australia and it also seems reasonable as the biggest market for Abbvie is the USA & Europe. Parallelly, the USA seems to be the main focused R&D center and is also the origin country of Abbvie.
Abbvie was founded in 2013. The company doing business in the Pharmaceutical Industry and offers a wide range of products in Biopharmaceutical, Biotechnology Biotherapeutics, Oncology, Immunology, Virology, Neuroscience, and Women’s Health, etc. As of December 2021, Abbvie has a market cap of $215.45 Billion.
Do read about some of the most popular patents of Abbvie which have been covered by us in this article and also you can find Abbvie patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Abbvie patent portfolio.
How many patents does Abbvie have?
Abbvie has a total of 47143 patents globally. These patents belong to 8138 unique patent families. Out of 47143 patents, 26893 patents are active.
How many Abbvie patents are Alive/Dead?
Worldwide Patents
How Many Patents did Abbvie File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Abbvie Applications Filed | Abbvie Patents Granted |
| 2011 | 3651 | 1017 |
| 2012 | 3375 | 1183 |
| 2013 | 2834 | 1327 |
| 2014 | 3319 | 1573 |
| 2015 | 2223 | 1559 |
| 2016 | 1935 | 1533 |
| 2017 | 1788 | 1365 |
| 2018 | 1454 | 1267 |
| 2019 | 884 | 1089 |
| 2020 | 756 | 1059 |
| 2021 | 259 | 791 |
Which Abbvie Drug Patents are Expiring in the Next 10 Years?
The patent no. US10028937B2 which is expiring in Jun, 2030, describes the process of manufacturing anti-viral compounds capable of inhibiting replication of Hepatitis C virus (HCV) thereby presenting a method for treatment of HCV infection.
Given below is the list of few drugs patented by Abbvie accompanied by a patent relevant to the drug which will be available for generic drug manufacturing and usage within the next/upcoming 10 years for treatment of various diseases and disorders.
| Drug Name | Patent Number | Patent Title | Patent Expiration |
| Mavyret | US10028937B2 | Anti-Viral Compounds | Jun, 2030 |
| Lumigan | US7851504B2 | Enhanced Bimatoprost Ophthalmic… | Jun, 2027 |
| Oriahnn | US11045470B2 | Methods of treating heavy menstrual… | Mar, 2034 |
| Orilissa | US10537572B2 | Methods of administering elagolix | Sep, 2036 |
| Qulipta | US9850246B2 | Process for making CGRP receptor… | Mar, 2033 |
Interested in knowing about Abbvie Drug Patents Expiring in the next 10 years?
How Many Patents did Abbvie File in Different Countries?
Countries in which Abbvie Filed Patents
| Country | Patents |
| United States Of America | 7989 |
| Europe | 3594 |
| Australia | 3165 |
| Japan | 2989 |
| Canada | 2667 |
| China | 2059 |
| Mexico | 1464 |
| Korea (South) | 1426 |
| Brazil | 1382 |
| Hong Kong (S.A.R.) | 1197 |
| Spain | 1106 |
| Israel | 1032 |
| Taiwan | 922 |
| Russian Federation | 904 |
| India | 847 |
| Singapore | 769 |
| New Zealand | 637 |
| South Africa | 637 |
| Argentina | 582 |
| Denmark | 564 |
| Germany | 502 |
| Poland | 446 |
| Turkey | 443 |
| Austria | 396 |
| Portugal | 383 |
| Peru | 363 |
| Chile | 355 |
| Slovenia | 283 |
| Malaysia | 275 |
| Philippines | 265 |
| Hungary | 258 |
| Ukraine | 257 |
| Norway | 251 |
| Dominican Republic | 234 |
| Viet Nam | 231 |
| Uruguay | 229 |
| Colombia | 220 |
| Costa Rica | 213 |
| Eurasian Patent Organization | 199 |
| Ecuador | 196 |
| Cyprus | 181 |
| Croatia | 166 |
| Thailand | 139 |
| Serbia | 104 |
| Lithuania | 95 |
| Morocco | 88 |
| Guatemala | 76 |
| United Kingdom | 69 |
| Saudi Arabia | 68 |
| Czech Republic | 41 |
| Montenegro | 37 |
| Slovakia | 35 |
| France | 30 |
| Iceland | 25 |
| Tunisia | 20 |
| San Marino | 20 |
| Panama | 19 |
| Bulgaria | 19 |
| Gulf Cooperation Council | 18 |
| Nicaragua | 13 |
| Luxembourg | 11 |
| Algeria | 11 |
| Georgia | 10 |
| Netherlands | 10 |
| African Regional Industrial Property Organization | 9 |
| Jordan | 7 |
| Sweden | 6 |
| Estonia | 5 |
| African Intellectual Property Organization | 4 |
| Republic of Moldova | 4 |
| El Salvador | 3 |
| Mongolia | 3 |
| Ireland | 2 |
| Switzerland | 2 |
| Egypt | 2 |
| Italy | 2 |
| Belgium | 2 |
| Kazakhstan | 2 |
| Belarus | 1 |
| Yugoslavia/Serbia and Montenegro | 1 |
| Cuba | 1 |
| Latvia | 1 |
| Honduras | 1 |
| Romania | 1 |
Where are Research Centers of Abbvie Patents Located?
10 Best Abbvie Patents
US6306423B1 is the most popular patent in the Abbvie portfolio. It has received 542 citations so far from companies like Allergan, Medtronic and Holaira Inc.
Below is the list of 10 most cited patents of Abbvie:
| Publication Number | Citation Count |
| US6306423B1 | 542 |
| US7612181B2 | 486 |
| US8963714B2 | 464 |
| WO2008039218A2 | 437 |
| US6312708B1 | 427 |
| US6316029B1 | 367 |
| WO2008121742A2 | 347 |
| US6375986B1 | 323 |
| US6699493B2 | 319 |
| US6726918B1 | 313 |
Which Companies are using Abbvie Patents to Advance their Research?
If patents or patents from a particular technology area of a company receive a lot of citations, it implies that the technology is being followed and incrementally innovated by the citing companies. It also indicates that citing companies are working on similar and closely related technologies.
The top citing companies in the Abbvie patent portfolio are Allergan Inc, Lifecell and Pharmacyclics.
List of the top forward citing Companies –
| Company | Number of Patents |
| Allergan Inc | 448 |
| Lifecell | 78 |
| Pharmacyclics | 51 |
| Merz Pharma Gmbh | 27 |
| Novartis | 27 |
| Genentech | 26 |
| Warsaw Orthopedic | 25 |
| Roche Holding | 25 |
| Boehringer Ingelheim International Gmbh | 24 |
| Zeltiq Aesthetics | 24 |
Count of 102 and 103 Type Rejections based on Abbvie Patents
Top Abbvie Patents used in Rejecting Most Patent Applications
| Patent Number | Count of Rejected Applications |
| US7612181B2 | 43 |
| US7815934B2 | 32 |
| US6503894B1 | 29 |
| US20040224406A1 | 27 |
| US20030138417A1 | 27 |
| US20090299328A1 | 26 |
| US6514267B2 | 23 |
| US7189507B2 | 22 |
| US9132031B2 | 20 |
| US8420081B2 | 19 |
| US10155108B2 | 18 |
| US8275442B2 | 17 |
| US7741476B2 | 17 |
| US20060073592A1 | 16 |
| US20040076955A1 | 16 |
What Percentage of Abbvie US Patent Applications were Granted?
Abbvie (Excluding its subsidiaries) has filed 2502 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 1856 have been granted leading to a grant rate of 77.4%.
Below are the key stats of Abbvie patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Abbvie?
| Law Firm | Total Application | Success Rate |
| Abbvie | 957 | 67.59% |
| Neal Gerber & Eisenberg | 260 | 77.82% |
| Mccarter & English | 183 | 57.06% |
| Polsinelli | 110 | 99.09% |
| Womble Bond Dickinson | 97 | 70.37% |
| Armstrong Teasdale | 90 | 70.24% |
| Foley Hoag | 90 | 58.14% |
| Dechert | 68 | 66.18% |
| Sterne Kessler Goldstein & Fox | 58 | 43.10% |
| Lathrop Gage | 46 | 54.35% |
EXCLUSIVE INSIGHTS COMING SOON
What are Abbvie’s key innovation segments?
What Technologies are Covered by Abbvie?
The chart below distributes patents filed by Abbvie in different countries on the basis of the technology protected in patents. It also represents the markets where Abbvie thinks it’s important to protect particular technology inventions
R&D Focus: How Abbvie search focus changed over the years?
Interested in knowing about the areas of innovation that are being protected by Abbvie?
EXCLUSIVE INSIGHTS COMING SOON